Vedanta Biosciences has “significantly reduced” its headcount to channel its remaining resources to its lead live bacteria ...

Friday, ImmunityBio said the two complete responses are ongoing after seven and 15 months. The patients received four cycles ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

The leaders of Chugai Pharmaceutical are tired of their company not getting its due. At the J.P. | The leaders of Chugai ...

Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may ...

Boston Scientific is capping off a busy week with a major buyout, entering a deal worth about $14.5 billion to acquire ...

Italian pharma Alfasigma has penned a 125 million euro ($145 million) deal for the rights to an injectable form of an investigational herpes simplex virus (HSV) encephalitis treatment. | Italian ...

Hopes were high Wednesday for a billion-dollar megadeal—the kind the J.P. Morgan Healthcare Conference is known for—but no ...

The Novo Nordisk Foundation is investing 5.5 billion Danish kroner ($860 million) in the BioInnovation Institute (BII) to help scale up more homegrown biotechs and deep tech companies. | The Novo ...

The J.P. Morgan Healthcare Conference, as well as Fierce's own JPM Week, roll into Wednesday with plenty more events, ...

With a White House drug pricing deal done and dusted and the threat of tariffs ameliorated, Sanofi is enjoying more clarity from the U.S. government now than the same time last year. But several ...

Charles River Laboratories has struck a $510 million deal to buy a non-human primate provider, furthering efforts to ...